Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Tolerance Study of Recombinant Human Albumin Injection in Healthy Subjects.

NCT04641364 is registered in ClinicalTrials.gov with The First Hospital of Jilin University as lead sponsor.

NCT NCT04641364
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04641364 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Tolerance Study of Recombinant Human Albumin Injection in Healthy Subjects.
Lead sponsor
The First Hospital of Jilin University
Phase
Phase 1
Overall status
Completed
Start date
June 24, 2019
Completion date
May 6, 2020
Enrollment
80 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ascites